RxDoctor Payments Data

Olamide Adeleye, NP

Nurse Practitioner · Southaven, MSNPI 1225379050

Payments from drug & device makers

$3,127in general payments, 2019–2025

Across 131 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$861
  • Mallinckrodt Hospital Products Inc.$447
  • Vifor Pharma, Inc.$419
  • Aurinia Pharma U.S., Inc.$352
  • Bayer$239
  • Akebia Therapeutics Inc$166
  • plus $642 from 10 others

What the payments were for

  • Food & beverage$2,99996%
  • Education$1284%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,127 in reported general payments places this provider in the 85th percentile of 1,090 nurse practitioner providers in Mississippi.

See all nurse practitioner providers in Mississippi

Medicare billing

Part B allowed, 2024
$34,929
Medicare patients
185
Services billed
360

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin170$207,558
FarxigaDapagliflozin Propanediol197$194,515
VeltassaPatiromer Calcium Sorbitex37$60,969
SpsSodium Polystyrene Sulfon/Sorb66$31,647
LokelmaSodium Zirconium Cyclosilicate15$10,588
DapagliflozinDapagliflozin Propanediol12$6,143
Calcitriol74$2,001
Cinacalcet Hcl44$1,748
Hydralazine Hcl119$1,057
Potassium Chloride48$952
Losartan Potassium115$769
Calcium Acetate20$737
Lisinopril71$462
Vitamin D2Ergocalciferol (Vitamin D2)60$423
Amlodipine Besylate66$258

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$23$207,558170 claims
AstraZenecaFarxiga, Lokelma$861$205,103212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,090 nurse practitioner providers in Mississippi.

Other nurse practitioner in Southaven

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →